Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer

被引：4
|
作者：
de Wit, Ronald [1 ]
Tombal, Bertrand [2 ]
Freedland, Stephen [3 ,4 ]
机构：
[1] Erasmus Univ, Med Ctr, Med Oncol, Rotterdam, Netherlands
[2] Catholic Univ Louvain, Inst Rech Clin, Louvain, Belgium
[3] Cedars Sinai Med Ctr, Div Urol, Los Angeles, CA 90048 USA
[4] Durham VA Med Ctr, Sect Urol, Durham, NC USA
来源：
EUROPEAN UROLOGY | 2021年 / 79卷 / 02期
关键词：
INCREASED SURVIVAL; ENZALUTAMIDE; ABIRATERONE;
D O I：
10.1016/j.eururo.2020.10.016
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：170 / 172
页数：3
相关论文
共 50 条
  • [31] Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis
    Roy, Soumyajit
    Sayyid, Rashid
    Saad, Fred
    Sun, Yilun
    Lajkosz, Katherine
    Ong, Michael
    Klaassen, Zachary
    Malone, Shawn
    Spratt, Daniel E.
    Wallis, Christopher J. D.
    Morgan, Scott C.
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (05): : 494 - 502
  • [32] Nomogram Analysis for Predicting Response to Androgen-Receptor-Axis-Targeted Therapies in Patients With Metastatic Castration-Resistant Prostate Cancer
    Shao, I-Hung
    Wang, Hsiang-Shen
    Hsieh, Chin-Hsuan
    Lee, Tsung-Lin
    Chang, Ying-Hsu
    Huang, Liang-Kang
    Chu, Yuan-Cheng
    Kan, Hung-Chen
    Lin, Po-Hung
    Yu, Kai-Jie
    Wu, Chun-Te
    Chuang, Cheng-Keng
    Pang, See-Tong
    CANCER MEDICINE, 2024, 13 (21):
  • [33] Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
    Beer, T. M.
    Armstrong, A. J.
    Rathkopf, D. E.
    Loriot, Y.
    Sternberg, C. N.
    Higano, C. S.
    Iversen, P.
    Bhattacharya, S.
    Carles, J.
    Chowdhury, S.
    Davis, I. D.
    de Bono, J. S.
    Evans, C. P.
    Fizazi, K.
    Joshua, A. M.
    Kim, C-S
    Kimura, G.
    Mainwaring, P.
    Mansbach, H.
    Miller, K.
    Noonberg, S. B.
    Perabo, F.
    Phung, D.
    Saad, F.
    Scher, H. I.
    Taplin, M-E
    Venner, P. M.
    Tombal, B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (05) : 424 - 433
  • [34] Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer
    Wenzel, Mike
    Hoeh, Benedikt
    Humke, Clara
    Cano Garcia, Cristina
    Siech, Carolin
    Steuber, Thomas
    Graefen, Markus
    Traumann, Miriam
    Kluth, Luis
    Chun, Felix K. H.
    Mandel, Philipp
    WORLD JOURNAL OF UROLOGY, 2024, 43 (01)
  • [35] Efficacy of androgen receptor signaling inhibitors in combination with androgen deprivation therapy for castration-sensitive metastatic prostate cancer: a retrospective analysis in a Japanese cohort
    Taga, Minekatsu
    Sasaki, Takeshi
    Higashi, Shinichiro
    Kimura, Shoichi
    Sawada, Atsuro
    Tsuchiyama, Katsuki
    Inoue, Takahiro
    Kamoto, Toshiyuki
    Terada, Naoki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (02) : 351 - 357
  • [36] Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review
    Yanagisawa, Takafumi
    Rajwa, Pawel
    Quhal, Fahad
    Kawada, Tatsushi
    Bekku, Kensuke
    Laukhtina, Ekaterina
    von Deimling, Markus
    Chlosta, Marcin
    Karakiewicz, Pierre I.
    Kimura, Takahiro
    Shariat, Shahrokh F.
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (04):
  • [37] Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors
    Suzuki, Kotaro
    Shiraishi, Yusuke
    Furukawa, Junya
    Okamura, Yasuyoshi
    Bando, Yukari
    Hara, Takuto
    Okada, Keisuke
    Terakawa, Tomoaki
    Hyodo, Yoji
    Chiba, Koji
    Teishima, Jun
    Nakano, Yuzo
    Miyake, Hideaki
    CLINICAL GENITOURINARY CANCER, 2024, 22 (05)
  • [38] Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
    Kostos, Louise
    Tran, Ben
    Azad, Arun A.
    DRUGS, 2024, 84 (09) : 1093 - 1109
  • [39] Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
    Matsubara, Nobuaki
    Yamada, Yoko
    Tabata, Ken-ichi
    Satoh, Takefumi
    Kamiya, Naoto
    Suzuki, Hiroyoshi
    Kawahara, Takashi
    Uemura, Hiroji
    Yano, Akihiro
    Kawakami, Satoru
    Otsuka, Masafumi
    Fukasawa, Satoshi
    CLINICAL GENITOURINARY CANCER, 2017, 15 (06) : E1073 - E1080
  • [40] Targeting persistent androgen receptor signaling in castration-resistant prostate cancer
    Graham, Laura
    Schweizer, Michael T.
    MEDICAL ONCOLOGY, 2016, 33 (05)
12345